Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Theralase Technologies ( (TSE:TLT) ) has shared an update.
Theralase reported interim Phase II clinical trial results for its light-activated Ruvidar treatment in BCG-unresponsive NMIBC carcinoma in situ, showing a complete response rate of 64.4% at any time point among evaluable patients and sustained responses of over 21% at two and three years, with a 100% safety profile over 450 days. The outcomes exceed International Bladder Cancer Group guidelines for clinically meaningful response and durability, supporting Theralase’s plan to compile full data in 2026 for submission to Health Canada and the FDA, positioning the company as a potential new treatment option for patients who currently face bladder removal as the primary alternative.
The most recent analyst rating on (TSE:TLT) stock is a Hold with a C$0.25 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.
Spark’s Take on TSE:TLT Stock
According to Spark, TipRanks’ AI Analyst, TSE:TLT is a Neutral.
The score is held down primarily by weak financial performance—very large losses versus a small and declining revenue base, ongoing cash burn, and substantial equity erosion. Technicals provide some support with strong recent momentum (price above major moving averages and positive MACD), but elevated RSI suggests the move may be stretched. Valuation remains unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on TSE:TLT stock, click here.
More about Theralase Technologies
Theralase Technologies Inc. is a clinical-stage pharmaceutical company focused on developing energy-activated small molecules, notably its light-activated compound Ruvidar, for the targeted destruction of cancer, bacteria and viruses. The company’s current lead program targets Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC), a high-risk segment with limited treatment options where standard-of-care often leads to radical cystectomy.
Average Trading Volume: 206,346
Technical Sentiment Signal: Buy
Current Market Cap: C$66.84M
For detailed information about TLT stock, go to TipRanks’ Stock Analysis page.